624 related articles for article (PubMed ID: 26188349)
1. Fragments of Citrullinated and MMP-degraded Vimentin and MMP-degraded Type III Collagen Are Novel Serological Biomarkers to Differentiate Crohn's Disease from Ulcerative Colitis.
Mortensen JH; Godskesen LE; Jensen MD; Van Haaften WT; Klinge LG; Olinga P; Dijkstra G; Kjeldsen J; Karsdal MA; Bay-Jensen AC; Krag A
J Crohns Colitis; 2015 Oct; 9(10):863-72. PubMed ID: 26188349
[TBL] [Abstract][Full Text] [Related]
2. Ulcerative colitis, Crohn's disease, and irritable bowel syndrome have different profiles of extracellular matrix turnover, which also reflects disease activity in Crohn's disease.
Mortensen JH; Manon-Jensen T; Jensen MD; Hägglund P; Klinge LG; Kjeldsen J; Krag A; Karsdal MA; Bay-Jensen AC
PLoS One; 2017; 12(10):e0185855. PubMed ID: 29028807
[TBL] [Abstract][Full Text] [Related]
3. Inflammatory Biomarkers of Extracellular Matrix Remodeling and Disease Activity in Crohn's Disease and Ulcerative Colitis.
Domislovic V; Høg Mortensen J; Lindholm M; Kaarsdal MA; Brinar M; Barisic A; Manon-Jensen T; Krznaric Z
J Clin Med; 2022 Oct; 11(19):. PubMed ID: 36233775
[TBL] [Abstract][Full Text] [Related]
4. Serological biomarkers of type I, III and IV collagen turnover are associated with the presence and future progression of stricturing and penetrating Crohn's disease.
Bourgonje AR; Alexdottir MS; Otten AT; Loveikyte R; Bay-Jensen AC; Pehrsson M; van Dullemen HM; Visschedijk MC; Festen EAM; Weersma RK; Karsdal MA; Faber KN; Mortensen JH; Dijkstra G
Aliment Pharmacol Ther; 2022 Aug; 56(4):675-693. PubMed ID: 35661188
[TBL] [Abstract][Full Text] [Related]
5. Misbalance in type III collagen formation/degradation as a novel serological biomarker for penetrating (Montreal B3) Crohn's disease.
van Haaften WT; Mortensen JH; Karsdal MA; Bay-Jensen AC; Dijkstra G; Olinga P
Aliment Pharmacol Ther; 2017 Jul; 46(1):26-39. PubMed ID: 28481042
[TBL] [Abstract][Full Text] [Related]
6. Association of Anti-glycan Antibodies and Inflammatory Bowel Disease Course.
Paul S; Boschetti G; Rinaudo-Gaujous M; Moreau A; Del Tedesco E; Bonneau J; Presles E; Mounsef F; Clavel L; Genin C; Flourié B; Phelip JM; Nancey S; Roblin X
J Crohns Colitis; 2015 Jun; 9(6):445-51. PubMed ID: 25895876
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA signatures differentiate Crohn's disease from ulcerative colitis.
Schaefer JS; Attumi T; Opekun AR; Abraham B; Hou J; Shelby H; Graham DY; Streckfus C; Klein JR
BMC Immunol; 2015 Feb; 16():5. PubMed ID: 25886994
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive assessment of ECM turnover using serum biomarkers establishes PBC as a high-turnover autoimmune liver disease.
Vesterhus M; Nielsen MJ; Hov JR; Saffioti F; Manon-Jensen T; Leeming DJ; Moum B; Boberg KM; Pinzani M; Karlsen TH; Karsdal MA; Thorburn D
JHEP Rep; 2021 Feb; 3(1):100178. PubMed ID: 33225252
[TBL] [Abstract][Full Text] [Related]
9. Peripheral cytokine profile in Chilean patients with Crohn's disease and ulcerative colitis.
Beltrán CJ; Candia E; Erranz B; Figueroa C; Gonzalez MJ; Quera R; Hermoso MA
Eur Cytokine Netw; 2009 Mar; 20(1):33-8. PubMed ID: 19318319
[TBL] [Abstract][Full Text] [Related]
10. Combined serological, genetic, and inflammatory markers differentiate non-IBD, Crohn's disease, and ulcerative colitis patients.
Plevy S; Silverberg MS; Lockton S; Stockfisch T; Croner L; Stachelski J; Brown M; Triggs C; Chuang E; Princen F; Singh S
Inflamm Bowel Dis; 2013 May; 19(6):1139-48. PubMed ID: 23518807
[TBL] [Abstract][Full Text] [Related]
11. Non-invasive biomarkers derived from the extracellular matrix associate with response to immune checkpoint blockade (anti-CTLA-4) in metastatic melanoma patients.
Jensen C; Madsen DH; Hansen M; Schmidt H; Svane IM; Karsdal MA; Willumsen N
J Immunother Cancer; 2018 Dec; 6(1):152. PubMed ID: 30567561
[TBL] [Abstract][Full Text] [Related]
12. Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America.
; ; Bousvaros A; Antonioli DA; Colletti RB; Dubinsky MC; Glickman JN; Gold BD; Griffiths AM; Jevon GP; Higuchi LM; Hyams JS; Kirschner BS; Kugathasan S; Baldassano RN; Russo PA
J Pediatr Gastroenterol Nutr; 2007 May; 44(5):653-74. PubMed ID: 17460505
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic precision of anti-Saccharomyces cerevisiae antibodies and perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease.
Reese GE; Constantinides VA; Simillis C; Darzi AW; Orchard TR; Fazio VW; Tekkis PP
Am J Gastroenterol; 2006 Oct; 101(10):2410-22. PubMed ID: 16952282
[TBL] [Abstract][Full Text] [Related]
14. Blood-based biomarkers used to predict disease activity in Crohn's disease and ulcerative colitis.
Burakoff R; Pabby V; Onyewadume L; Odze R; Adackapara C; Wang W; Friedman S; Hamilton M; Korzenik J; Levine J; Makrauer F; Cheng C; Smith HC; Liew CC; Chao S
Inflamm Bowel Dis; 2015 May; 21(5):1132-40. PubMed ID: 25895006
[TBL] [Abstract][Full Text] [Related]
15. PR3-ANCA and panel diagnostics in pediatric inflammatory bowel disease to distinguish ulcerative colitis from Crohn's disease.
Horn MP; Peter AM; Righini Grunder F; Leichtle AB; Spalinger J; Schibli S; Sokollik C
PLoS One; 2018; 13(12):e0208974. PubMed ID: 30557305
[TBL] [Abstract][Full Text] [Related]
16. Remodeling of the Tumor Microenvironment Predicts Increased Risk of Cancer in Postmenopausal Women: The Prospective Epidemiologic Risk Factor (PERF I) Study.
Bager CL; Willumsen N; Kehlet SN; Hansen HB; Bay-Jensen AC; Leeming DJ; Dragsbæk K; Neergaard JS; Christiansen C; Høgdall E; Karsdal M
Cancer Epidemiol Biomarkers Prev; 2016 Sep; 25(9):1348-55. PubMed ID: 27411352
[TBL] [Abstract][Full Text] [Related]
17. Extracellular Matrix Fragments of the Basement Membrane and the Interstitial Matrix Are Serological Markers of Intestinal Tissue Remodeling and Disease Activity in Dextran Sulfate Sodium Colitis.
Lindholm M; Manon-Jensen T; Madsen GI; Krag A; Karsdal MA; Kjeldsen J; Mortensen JH
Dig Dis Sci; 2019 Nov; 64(11):3134-3142. PubMed ID: 31123972
[TBL] [Abstract][Full Text] [Related]
18. Protein fingerprinting of the extracellular matrix remodelling in a rat model of liver fibrosis--a serological evaluation.
Leeming DJ; Byrjalsen I; Jiménez W; Christiansen C; Karsdal MA
Liver Int; 2013 Mar; 33(3):439-47. PubMed ID: 23279004
[TBL] [Abstract][Full Text] [Related]
19. Matrix metalloproteinase-9: its interplay with angiogenic factors in inflammatory bowel diseases.
Matusiewicz M; Neubauer K; Mierzchala-Pasierb M; Gamian A; Krzystek-Korpacka M
Dis Markers; 2014; 2014():643645. PubMed ID: 24803722
[TBL] [Abstract][Full Text] [Related]
20. The impact of matrix metalloproteinases and their tissue inhibitors in inflammatory bowel diseases.
Lakatos G; Hritz I; Varga MZ; Juhász M; Miheller P; Cierny G; Tulassay Z; Herszényi L
Dig Dis; 2012; 30(3):289-95. PubMed ID: 22722554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
